Navigation Links
Cystatin C Test- A Reliable Test to Detect Chronic Health Risks

The Cystatin C test appears to be a good alternative for identifying risks for kidney disease, cardiovascular disease, that the creatinine test might miss//. A study conducted by a researcher at the San Francisco VA Medical Center, has shown the inefficacy of routine kidney function test that is incapable of picking up chronic health risks among the elderly.

"For the clinician who treats older people or others at risk for kidney disease, this is an important message: A normal creatinine level should not reassure you that your patient has normal kidney function," says lead author Michael Shlipak, MD, chief of general internal medicine at SFVAMC and an associate professor of medicine, epidemiology, and biostatistics at the University of California, San Francisco. "It shows that cystatin is a very promising new tool that complements creatinine in the ongoing effort to detect early kidney disease and prevent its complications."

The study appears in the August 15, 2006 issue of Annals of Internal Medicine.

Shlipak and his colleagues tested blood samples from 4,663 elders living independently in the community who participated in the Cardiovascular Health Study, a national longitudinal study of people aged 65 and older sponsored by the National Institutes of Health.

The researchers measured each participant's creatinine – an end-product of muscle metabolism that is filtered through the kidneys and has been a standard marker of kidney health for "probably 100 years," according to Shlipak – and cystatin C, a blood protein that is also filtered through the kidneys. They then matched test results with health outcomes up to nine years later.

Among participants with no diagnosed chronic kidney disease, those with high levels of cystatin C had significantly greater risk for poor health than those with normal cystatin C levels. Individuals in the high cystatin group were 50 percent more likely to die overall, nearly twice as l ikely to die of cardiovascular problems, and 30 percent more likely to die of non-cardiovascular problems. They had increased risks of 40 percent for heart failure, 30 percent for heart attack, and 20 percent for stroke. Finally, they were more than three times more likely to develop chronic kidney disease.

"In contrast," the researchers report, "creatinine concentrations had associations with each outcome that were much weaker, and significant only for the outcome of cardiovascular death."

Shlipak says, "This tells us that the creatinine test, while broadly useful as a measure of kidney health, is insensitive. If a creatinine level is high, that's probably an indication of kidney disease. But if it's low, you don't know. You would need to do a cystatin test if there's any other indication of kidney disease or if the patient is in a group that's at risk."

Groups at risk for chronic kidney disease include people over 65, people with diabetes, hypertension, or cardiovascular disease, and African Americans, American Indians, and Hispanic Americans.

"This is also telling us that kidney function declines much more with age than we realized before," adds Shlipak. He terms this syndrome "pre-clinical kidney disease," or pre-CKD.

"We have the tools to slow kidney disease," he notes, including blood pressure control, sugar control for diabetes, and specific medications known as ACE inhibitors. "It's well-established that end-stage kidney disease is rising at a rate of 10 to 20 percent per year. With a heightened awareness of pre-CKD, we can be more aggressive in taking steps to prevent it."

Accurate knowledge of kidney function is also a matter of patient safety, according to Shlipak: "Surgery, some other medical procedures, and certain medications all can have an adverse impact on kidney health."

The cystatin test itself is relatively inexpensive and already widely available, he says. "As deman d for it increases, it should become even more commonly available."

The next steps for researchers, says Shlipak, should include longitudinal studies that determine whether a screening test for cystatin C can improve clinical care and health outcomes for large patient populations. "We also want to map out the physiologic consequences of early mild kidney dysfunction, now that we can measure it."

Source : Eureka Alert


'"/>




Related medicine news :

1. Test-tube babies show no emotional problems
2. First Test-tube Baby Set to Become a Mother Herself
3. Shortness Of Breath A More Reliable Indicator Of High Risk Cardiac Disease
4. Are Conventional Tests for Heart attacks Reliable?
5. Reliable Help For Smokers From Nicotine Patches and Former Smokers
6. Parents – Teen’s Most Reliable Source for Sex Educatin
7. Male Contraceptives-Soon to be Reliable and Reversible
8. Are Alternative Therapies A Reliable Alternative?
9. Doctors Find Internet A Reliable Tool For Diagnosing Diseases
10. Mifepristone Reliable For Treating Uterine Fibroids
11. Are Computer-aided Mammogram Reports Reliable?
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... , ... April 25, 2017 , ... There is no ... Hospital, according to a special report in the May issue of Consumer Reports focused ... highest quality ranking for results achieved during and after coronary bypass and aortic valve ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... solutions, announces the continuation of its strategic partnership with and platinum sponsorship of ... nations in the safe and effective management of complex spine deformity cases, particularly ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... As ... Memorial Museum today to honor the victims of the Holocaust and Nazi persecution, ... ceremonies at Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: